Inventiva Secures €20.1M in Funding to Advance NASH Treatment
Inventiva Secures €20.1M in Funding to Advance NASH Treatment
inventiva获得2010万欧元的资金以推进NASH治疗
Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the issuance of royalty certificates (the "Royalty Certificates") subscribed by Samsara BioCapital, BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of approximately €20.1 million (the "Transaction").
Inventiva（纳斯达克：IVA）（"Inventiva"或"公司"），一家专注于开发口服小分子疗法治疗代谢功能障碍脂肪肝（"MASH"），又称非酒精性脂肪肝（"NASH"）患者以及其他存在重大未满足医疗需求的疾病的临床阶段生物制药公司，今天宣布发行由Samsara BioCapital，BVF Partners，NEA，Sofinnova和Yiheng认购的版税证书（"Royalty Certificates"），金额为约€2010万（"交易"）。
Frederic Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva stated: "Besides extending our cash runway, this agreement demonstrates the commitment from our key shareholders...
Inventiva的董事长，首席执行官兼联合创始人...
登录免费看全文
登录/注册